- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00236392
A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)
November 29, 2010 updated by: Janssen Pharmaceutica N.V., Belgium
Double-Blind Placebo-Controlled Randomized Withdrawal Trial Assessing the Efficacy and Tolerability of "On-Demand" Maintenance Therapy With 10mg o.d. Rabeprazole for 6 Months in Non-Erosive Reflux Disease Patients With Complete Symptom Relief After 4 Week Open Acute Phase
The purpose of this study is to assess the efficacy and safety of long-term, "on-demand" maintenance therapy with rabeprazole in patients with non-erosive reflux disease (NERD).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
More than half of patients with typical gastroesophageal reflux symptoms such as heartburn are considered to have non-erosive reflux disease (NERD), which is characterized by a lack of clinically defined damage to the esophagus.
One approach to maintain control of these symptoms is to have medication available "on-demand."
This is a double-blind, placebo-controlled study of the effectiveness of "on-demand" rabeprazole in the long-term maintenance of heartburn control in NERD patients, for whom heartburn was resolved with short-term, daily rabeprazole therapy.
The study has two phases: an acute phase (4 weeks) during which patients receive rabeprazole medication daily, and an "on-demand" phase (6 months) during which patients take medication (rabeprazole or placebo) as needed.
Only patients who have complete resolution of heartburn at the end of the acute phase are eligible to continue in the "on-demand" phase.
Efficacy assessments include the proportion of patients discontinuing treatment in the "on-demand" phase because of insufficient heartburn control, and the severity of heartburn and patient satisfaction determined at the beginning and end of "on-demand" phase.
Safety assessments include incidence of adverse events throughout the study, physical examination at study initiation, and vital signs at the beginning and the end of the study.
The study hypothesis is that "on-demand" therapy with rabeprazole is superior to placebo in maintaining heartburn control and is well tolerated by the patients with NERD.
Rabeprazole tablet (10 milligrams[mg]) once daily in the morning for 4 weeks.
Rabeprazole tablets (10mg) once daily on an "on-demand" basis for the following 6 months.
Study Type
Interventional
Enrollment (Actual)
422
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Minimum of 12 months history of heartburn as the predominant symptom with at least 2 symptomatic episodes
- Negative endoscopy (no erosive lesions according to the Modified Savary-Miller scale) within 7 days prior to acute treatment
- at least 3 days with moderate to very severe heartburn within one week prior to acute treatment
Exclusion Criteria:
- No known gastro-duodenal ulcer
- no infections, inflammations, or obstruction of the small or large intestine
- no history of gastrointestinal cancer, or prior surgery of the stomach or intestine
- no stomach or abdominal pain or discomfort as the predominant symptom or that requires treatment
- no history of erosive reflux causing inflammation of the esophagus
- no stricture of the esophagus, stomach, or any condition that causes difficulty in swallowing
- no history of non-erosive reflux disease (NERD) that is or was refractory to an adequate treatment course (1 month) with proton pump inhibitors
- no females who are pregnant or those lacking adequate contraception
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Proportion of patients discontinuing treatment in "on-demand" phase (6 months) because of insufficient heartburn control.
|
Secondary Outcome Measures
Outcome Measure |
---|
Severity and control of heartburn, overall quality of life (Psychological General Well-Being Index), antacid consumption, and patient satisfaction at the beginning and end of the "on-demand" phase. Incidence of adverse events throughout study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2001
Study Completion (Actual)
October 1, 2002
Study Registration Dates
First Submitted
October 7, 2005
First Submitted That Met QC Criteria
October 7, 2005
First Posted (Estimate)
October 12, 2005
Study Record Updates
Last Update Posted (Estimate)
November 30, 2010
Last Update Submitted That Met QC Criteria
November 29, 2010
Last Verified
November 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Signs and Symptoms, Digestive
- Gastrointestinal Diseases
- Esophageal Motility Disorders
- Deglutition Disorders
- Esophageal Diseases
- Gastroesophageal Reflux
- Heartburn
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Gastrointestinal Agents
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Rabeprazole
Other Study ID Numbers
- CR003121
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastroesophageal Reflux
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedGastroesophageal Reflux Disease | GERD | Acid Reflux | RefluxUnited States
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
Klinikum Garmisch-PatenkirchenNot yet recruitingReflux, Gastroesophageal | Gastro-esophageal RefluxGermany
-
Mansoura UniversityWithdrawnGastroesophageal Reflux Disease
-
Cliniques universitaires Saint-Luc- Université...UnknownGastroesophageal Reflux DiseaseBelgium
-
TakedaTerminatedGastroesophageal Reflux Disease | Non-erosive Reflux DiseaseSwitzerland, Netherlands
-
Vanderbilt University Medical CenterCompletedGastroesophageal Reflux Disease (GERD) | Non-erosive Reflux Disease (NERD)United States
-
Scandinavia PharmaRecruitingGastroesophageal Reflux DiseaseColombia
-
King Chulalongkorn Memorial HospitalCompleted
Clinical Trials on rabeprazole
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Eisai Inc.CompletedGastroesophageal Reflux DiseaseUnited States
-
Inje UniversityWithdrawnGastroesophageal Reflux DiseaseKorea, Republic of
-
The Catholic University of KoreaJanssen Korea, Ltd., KoreaCompletedEarly Gastric Adenocarcinoma | Adenocarcinoma, TubularKorea, Republic of
-
Janssen Research & Development, LLCEisai Inc.CompletedGastroesophageal Reflux Disease (GERD)United States, Poland, United Kingdom, Belgium, Brazil
-
Yungjin Pharm. Co., Ltd.Seoul National University HospitalCompletedGastroesophageal Reflux DiseaseKorea, Republic of
-
Seoul National University HospitalIlDong Pharmaceutical Co LtdCompletedEsophageal DiseaseKorea, Republic of
-
Eisai Co., Ltd.Completed
-
Eisai Inc.CompletedSymptomatic Gastroesophageal Reflux Disease (sGERD)United States